A number of other research analysts also recently weighed in on CELG. Oppenheimer Holdings, Inc. reiterated an outperform rating and set a $175.00 target price on shares of Celgene Corporation in a report on Wednesday, August 9th. Vetr upgraded Celgene Corporation from a buy rating to a strong-buy rating and set a $148.32 target price on the stock in a report on Wednesday, August 16th. Cantor Fitzgerald reiterated a buy rating and set a $162.00 target price on shares of Celgene Corporation in a report on Tuesday, September 26th. Jefferies Group LLC reiterated a buy rating and set a $160.00 target price on shares of Celgene Corporation in a report on Monday, July 31st. Finally, BMO Capital Markets boosted their price target on Celgene Corporation from $148.00 to $155.00 and gave the stock an outperform rating in a research report on Friday. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have assigned a buy rating and two have given a strong buy rating to the company. Celgene Corporation currently has an average rating of Buy and an average price target of $139.87.
Celgene Corporation (NASDAQ CELG) opened at $103.15 on Friday. The company has a market capitalization of $81,210.00, a PE ratio of 16.27, a PEG ratio of 0.80 and a beta of 1.79. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. Celgene Corporation has a twelve month low of $94.55 and a twelve month high of $147.17.
Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The company had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter in the previous year, the business earned $1.58 EPS. Celgene Corporation’s revenue was up 10.2% compared to the same quarter last year. research analysts expect that Celgene Corporation will post 6.67 EPS for the current year.
In other Celgene Corporation news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the sale, the insider now owns 3,925 shares of the company’s stock, valued at $564,768.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Michael D. Casey sold 9,250 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $139.03, for a total transaction of $1,286,027.50. Following the transaction, the director now directly owns 9,250 shares in the company, valued at $1,286,027.50. The disclosure for this sale can be found here. In the last three months, insiders sold 20,227 shares of company stock valued at $2,843,956. 0.95% of the stock is owned by insiders.
Several large investors have recently modified their holdings of CELG. Marble Harbor Investment Counsel LLC increased its position in shares of Celgene Corporation by 3.9% during the first quarter. Marble Harbor Investment Counsel LLC now owns 6,735 shares of the biopharmaceutical company’s stock worth $838,000 after acquiring an additional 250 shares during the period. Pioneer Investment Management Inc. increased its position in shares of Celgene Corporation by 15.7% during the first quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock worth $650,911,000 after acquiring an additional 710,584 shares during the period. Jaffetilchin Investment Partners LLC increased its position in shares of Celgene Corporation by 5.5% during the first quarter. Jaffetilchin Investment Partners LLC now owns 3,045 shares of the biopharmaceutical company’s stock worth $379,000 after acquiring an additional 160 shares during the period. CIBC World Markets Inc. increased its position in shares of Celgene Corporation by 27.5% during the first quarter. CIBC World Markets Inc. now owns 105,626 shares of the biopharmaceutical company’s stock worth $13,143,000 after acquiring an additional 22,764 shares during the period. Finally, Holderness Investments Co. purchased a new position in shares of Celgene Corporation during the first quarter worth approximately $205,000. 79.48% of the stock is currently owned by institutional investors and hedge funds.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.